Goodkin re-elected to serve with AIDS Clinical Trial Group Network

Dr. Karl Goodkin

JOHNSON CITY (Feb. 3, 2015) – Dr. Karl Goodkin, professor and chair of the Department of Psychiatry and Behavioral Sciences at East Tennessee State University’s Quillen College of Medicine, has been re-elected to serve a second term as an investigator on the Neurology Collaborative Science Group within the AIDS Clinical Trial Group (ACTG) Network.

The ACTG was initially established in 1987 to broaden the scope of the AIDS research effort of the National Institute of Allergy and Infectious Diseases. The ACTG supports the largest network of expert clinical and translational investigators and therapeutic clinical trials units in the world.

Investigators working with the ACTG serve as the major resource for HIV/AIDS research, treatment, care, training and education in their communities.

The mission of the organization is to develop and conduct scientifically rigorous translational research and therapeutic clinical trials that investigate the viral and immune pathogenesis of HIV infection; evaluate novel therapeutic agents and the most effective strategies for the use of existing treatments of HIV; evaluate interventions to treat and prevent HIV-related infections; and publish and disseminate the findings of these studies to improve clinical care, prevent or delay the progression of the disease and reduce or eliminate the mortality associated with HIV.

Goodkin has worked with this group for a number of years, even before it was transformed into an elected committee position. He has participated on ACTG study teams and in published papers on pain associated with peripheral neuropathy due to HIV, the toxicity of an HIV medicine called efavirenz and in clinical trials of other drugs used to treat HIV-associated neurocognitive disorder.

“Over my coming term, it is my plan to study the relationship of depression to cognitive impairment in persons living with HIV and the relationship of depression to lack of adherence to anti-HIV medications in women,” said Goodkin, who has an extensive background in HIV/AIDS research as it relates to mental health.

Goodkin joined ETSU last year, moving to the area from Los Angeles where he served as the director of mental health at the global, not-for-profit AIDS Healthcare Foundation (AHF).

His second term with the ACTG will run through November 2016. For more information about the ACTG, visit www.actgnetwork.org.

direct edit